Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Total Liabilities (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Total Liabilities for 7 consecutive years, with $25.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 5.46% year-over-year to $25.5 million, compared with a TTM value of $25.5 million through Dec 2025, down 5.46%, and an annual FY2025 reading of $25.5 million, down 5.46% over the prior year.
  • Total Liabilities was $25.5 million for Q4 2025 at aTYR PHARMA, down from $26.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $30.2 million in Q4 2023 and bottomed at $5.6 million in Q1 2021.
  • Average Total Liabilities over 5 years is $20.3 million, with a median of $25.0 million recorded in 2024.
  • The sharpest move saw Total Liabilities crashed 55.16% in 2021, then skyrocketed 323.93% in 2023.
  • Year by year, Total Liabilities stood at $6.4 million in 2021, then skyrocketed by 282.19% to $24.5 million in 2022, then rose by 23.19% to $30.2 million in 2023, then dropped by 10.55% to $27.0 million in 2024, then fell by 5.46% to $25.5 million in 2025.
  • Business Quant data shows Total Liabilities for ATYR at $25.5 million in Q4 2025, $26.6 million in Q3 2025, and $26.9 million in Q2 2025.